News
MRUS
46.86
-3.84%
-1.87
Merus NV Shareholders Endorse Governance and Incentive Plans
TipRanks · 10h ago
Halozyme Therapeutics (HALO) Q1 Earnings Beat Estimates
NASDAQ · 1d ago
FDA accepts Merus application for Zeno for lung, pancreatic cancer
Seeking Alpha · 2d ago
Merus Announces U.S. FDA Acceptance And Priority Review Of BLA For Zeno For The Treatment Of NRG1+ NSCLC And PDAC
The FDA has accepted for priority review a Biologics License Application for the bispecific antibody zenocutuzumab in patients with neuregulin 1 fusion cancer. Merus is a clinical-stage oncology company developing innovative antibodies. Zeno has the potential to be the first targeted therapy for patients with NRG1+ lung and pancreatic cancer.
Benzinga · 2d ago
MERUS ANNOUNCES U.S. FDA ACCEPTANCE AND PRIORITY REVIEW OF BIOLOGICS LICENSE APPLICATION FOR ZENO FOR THE TREATMENT OF NRG1+ NSCLC AND PDAC
Reuters · 2d ago
Weekly Report: what happened at MRUS last week (0429-0503)?
Weekly Report · 2d ago
Weekly Report: what happened at MRUS last week (0422-0426)?
Weekly Report · 04/29 12:09
Merus (MRUS) Moves 7.1% Higher: Will This Strength Last?
NASDAQ · 04/26 11:58
Weekly Report: what happened at MRUS last week (0415-0419)?
Weekly Report · 04/22 11:54
RSI Alert: Merus (MRUS) Now Oversold
NASDAQ · 04/16 20:26
Weekly Report: what happened at MRUS last week (0408-0412)?
Weekly Report · 04/15 11:44
Merus Price Target Maintained With a $66.00/Share by Needham
Dow Jones · 04/11 09:52
Needham Reiterates Buy on Merus, Maintains $66 Price Target
Benzinga · 04/11 09:42
Analysts Have Conflicting Sentiments on These Healthcare Companies: ZimVie Inc (ZIMV) and Merus (MRUS)
TipRanks · 04/11 09:40
Merus Presents Preclinical Data Demonstrating Efficacy Of Zeno In Cancer Models With High NRG1 Expression At The AACR Annual Meeting 2024
Merus announced preclinical data on zenocutuzumab in cancer models with high neuregulin 1 (NRG1) expression were presented at the American Association of Cancer Research Annual Meeting 2024. Zeno, a HER2 × HER3 bispecific antibody, is effective in cancer model with high NRG1 expression. Merus is a clinical-stage oncology company developing innovative antibodies.
Benzinga · 04/08 16:03
Weekly Report: what happened at MRUS last week (0401-0405)?
Weekly Report · 04/08 11:50
Weekly Report: what happened at MRUS last week (0325-0329)?
Weekly Report · 04/01 11:47
Merus Initiated at Buy by Truist Securities
Dow Jones · 03/28 15:43
Truist Securities Initiates Coverage On Merus with Buy Rating, Announces Price Target of $69
Benzinga · 03/28 15:34
Weekly Report: what happened at MRUS last week (0318-0322)?
Weekly Report · 03/25 11:50
More
Webull provides a variety of real-time MRUS stock news. You can receive the latest news about Merus through multiple platforms. This information may help you make smarter investment decisions.
About MRUS
Merus NV is the Netherlands - based biotechnology company, concentrated on developing differentiating therapeutics for cancer patients. The product programs in the Merus pipeline are based on the Multiclonics format. Its products are designed to bind to multiple targets, and are manufactured with features for anti-cancer effects against the complex mechanisms that drive cancer. Company's products engage cancer antigens and harness the power of the immune system to kill tumor cells by utilizing technology platform. One of the drug zenocutuzumab (Zeno), a Biclonics antibody, concentrates on helping patients with lung, pancreatic and other types of solid tumors. The company operates in the Netherlands and United States.